Cetera Trust Company N.A Acquires 435 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Cetera Trust Company N.A lifted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 17.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,955 shares of the biopharmaceutical company’s stock after acquiring an additional 435 shares during the period. Cetera Trust Company N.A’s holdings in Intra-Cellular Therapies were worth $247,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Wasatch Advisors LP boosted its holdings in Intra-Cellular Therapies by 3.5% in the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after acquiring an additional 130,351 shares in the last quarter. Bellevue Group AG lifted its position in Intra-Cellular Therapies by 0.6% during the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock worth $181,873,000 after acquiring an additional 14,342 shares during the period. State Street Corp increased its holdings in shares of Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after purchasing an additional 56,664 shares during the period. Franklin Resources Inc. increased its holdings in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after buying an additional 155,655 shares during the period. Finally, Perceptive Advisors LLC increased its holdings in Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after buying an additional 661,052 shares during the period. 92.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ITCI. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Morgan Stanley raised their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Needham & Company LLC reissued a “hold” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, January 13th. JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Finally, Royal Bank of Canada boosted their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.31.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.5 %

Shares of ITCI opened at $127.15 on Wednesday. The stock’s 50 day moving average is $89.99 and its two-hundred day moving average is $81.30. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.00. The firm has a market capitalization of $13.48 billion, a PE ratio of -146.11 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company’s revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.25) EPS. On average, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.